252 related articles for article (PubMed ID: 9542929)
1. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.
Tenover FC; Lancaster MV; Hill BC; Steward CD; Stocker SA; Hancock GA; O'Hara CM; McAllister SK; Clark NC; Hiramatsu K
J Clin Microbiol; 1998 Apr; 36(4):1020-7. PubMed ID: 9542929
[TBL] [Abstract][Full Text] [Related]
2. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
[TBL] [Abstract][Full Text] [Related]
3. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
Vaudaux P; Huggler E; Bernard L; Ferry T; Renzoni A; Lew DP
Antimicrob Agents Chemother; 2010 Sep; 54(9):3861-70. PubMed ID: 20547791
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Brazilian staphylococcal strains to glycopeptides evaluated by different testing methods.
Ferreira Nunes AP; Martins Teixeira L; Reis Bastos CC; de Souza Fonseca L; Netto dos Santos KR
Curr Microbiol; 2002 Jun; 44(6):385-90. PubMed ID: 12000986
[TBL] [Abstract][Full Text] [Related]
5. Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin.
Kohner PC; Patel R; Uhl JR; Garin KM; Hopkins MK; Wegener LT; Cockerill FR
J Clin Microbiol; 1997 Dec; 35(12):3258-63. PubMed ID: 9399530
[TBL] [Abstract][Full Text] [Related]
6. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
Tabe Y; Nakamura A; Igari J
J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.
Swenson JM; Anderson KF; Lonsway DR; Thompson A; McAllister SK; Limbago BM; Carey RB; Tenover FC; Patel JB
J Clin Microbiol; 2009 Jul; 47(7):2013-7. PubMed ID: 19420170
[TBL] [Abstract][Full Text] [Related]
8. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.
Hubert SK; Mohammed JM; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
J Clin Microbiol; 1999 Nov; 37(11):3590-3. PubMed ID: 10523558
[TBL] [Abstract][Full Text] [Related]
9. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital.
Nakipoglu Y; Derbentli S; Cagatay AA; Katranci H
BMC Infect Dis; 2005 May; 5():31. PubMed ID: 15871748
[TBL] [Abstract][Full Text] [Related]
10. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.
Biavasco F; Vignaroli C; Lazzarini R; Varaldo PE
Antimicrob Agents Chemother; 2000 Nov; 44(11):3122-6. PubMed ID: 11036034
[TBL] [Abstract][Full Text] [Related]
11. Validation of Vitek version 7.01 software for testing staphylococci against vancomycin.
Raney PM; Williams PP; McGowan JE; Tenover FC
Diagn Microbiol Infect Dis; 2002 Jun; 43(2):135-40. PubMed ID: 12088621
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of staphylococci and enterococci to glycopeptides comparison of 3 test methods.
Jansen B; Schumacher-Perdreau F; Pulverer G
Zentralbl Bakteriol; 1995 Oct; 282(4):402-8. PubMed ID: 9810663
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.
Vedel G; Leruez M; Lémann F; Hraoui E; Ratovohery D
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):820-2. PubMed ID: 2150815
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.
Walsh TR; Bolmström A; Qwärnström A; Ho P; Wootton M; Howe RA; MacGowan AP; Diekema D
J Clin Microbiol; 2001 Jul; 39(7):2439-44. PubMed ID: 11427551
[TBL] [Abstract][Full Text] [Related]
15. Glycopeptide resistance in coagulase-negative staphylococci.
Biavasco F; Vignaroli C; Varaldo PE
Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
Del' Alamo L; Cereda RF; Tosin I; Miranda EA; Sader HS
Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
[TBL] [Abstract][Full Text] [Related]
17. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.
Climo MW; Patron RL; Archer GL
Antimicrob Agents Chemother; 1999 Jul; 43(7):1747-53. PubMed ID: 10390234
[TBL] [Abstract][Full Text] [Related]
18. Low-level resistance to glycopeptides amongst staphylococcus species: surveillance in a university hospital and evaluation of a vancomycin screening agar.
Park YJ; Jun Park J; Lee SO; Oh EJ; Kee Kim B
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):155-9. PubMed ID: 11750170
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
Sahm DF; Kissinger J; Gilmore MS; Murray PR; Mulder R; Solliday J; Clarke B
Antimicrob Agents Chemother; 1989 Sep; 33(9):1588-91. PubMed ID: 2554802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
